

information. The total annual burden hours estimated for this ICR are summarized in the table below.

## TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name	Number of respondents	Number of responses per respondent	Total responses	Hours per respondent	Total burden hours
<b>Hospital Enrollment, Additions &amp; Recertifications</b>					
340B Program Registrations & Certifications for Hospitals *	248	1	248	2.00	496
Certifications to Enroll Hospital Outpatient Facilities .....	665	8	5,320	0.50	2,660
Hospital Annual Recertifications .....	2,481	10	24,810	0.25	6,202
<b>Registrations and Recertifications for Entities Other Than Hospitals</b>					
340B Registrations for Community Health Centers * .....	360	3	1,080	1.00	1,080
340B Registrations for STD/TB Clinics * .....	535	1	535	1.00	535
340B Registrations for Various Other Eligible Entity Types * .....	392	1	392	1.00	392
Community Health Center Annual Recertifications .....	1,277	7	8,939	0.25	2,235
STD & TB Annual Recertifications .....	4,033	1	4,033	0.25	1,008
Annual Recertification for entities other than Hospitals, Community Health Centers, and STD/TB Clinics .....	4,472	1	4,472	0.25	1,118
<b>Contracted Pharmacy Services Registration &amp; Recertifications</b>					
Contracted Pharmacy Services Registration .....	2,048	11	22,528	1.00	22,528
<b>Other Information Collections</b>					
Submission of Administrative Changes for any Covered Entity .....	19,322	1	19,322	** 0.25	4,831
Submission of Administrative Changes for any Manufacturer .....	350	1	350	0.50	175
Pharmaceutical Pricing Agreement and PPA Addendum ...	200	1	200	1.00	200
Total .....	36,383	.....	92,229	.....	43,460

\* Revised since last OMB submission, but burden was not affected.

\*\* Burden changed from .5 to .25 due to the 340B OPAS improvement.

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Amy McNulty,**

*Acting Director, Division of the Executive Secretariat.*

[FR Doc. 2019-09601 Filed 5-8-19; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Tick-Borne Disease Working Group

**AGENCY:** Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the Tick-Borne Disease Working Group (Working Group) will hold a meeting. The meeting will be open to the public. For this meeting, Working Group members will focus on plans to develop the next report to the HHS Secretary and Congress on federal tick-borne activities and research, taking into consideration the 2018 report. The 2020 report will also address a wide range of federal activities and research related to tick-borne diseases, such as, surveillance, prevention, diagnosis, diagnostics, and treatment; identify gaps in tick-borne disease research; and provide recommendations to the HHS Secretary regarding changes or improvements to such activities and research. In developing the report, the Working Group will solicit stakeholder input.

**DATES:** The meeting will be held on June 4, 2019, from 8:30 a.m. to 5:00 p.m. ET (times are tentative and subject to change). The confirmed times and agenda items for the meeting will be

posted on the website for the Working Group at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2019-6-4/index.html> when this information becomes available.

**ADDRESSES:** The meeting will be held at the Holiday Inn Washington-Capitol, 550 C Street SW, Washington, DC 20024. Members of the public may also attend the meeting via webcast. Instructions for attending via webcast will be posted one week prior to the meeting at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2019-6-4/index.html>.

**FOR FURTHER INFORMATION CONTACT:** James Berger, Designated Federal Officer for the Working Group; Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Mary E Switzer Building, 330 C Street SW, Suite L100, Washington, DC 20024. Email: [tickborne.disease@hhs.gov](mailto:tickborne.disease@hhs.gov); Phone: 202-795-7697.

**SUPPLEMENTARY INFORMATION:** In-person attendance at the meeting is limited to space available; therefore, preregistration for public members is advisable and can be accomplished by

registering at <https://www.eventbrite.com/e/tick-borne-disease-working-group-meeting-june-4-2019-meeting-9-tickets-60745681970>. On the day of the meeting, seating will be provided first to persons who have preregistered. People who have not preregistered will be accommodated on a first come, first served basis if additional seats are still available 10 minutes before the meeting starts. Non-U.S. citizens who plan to attend in person are required to provide additional information and must notify the Working Group support staff via email at [tickbornedisease@hhs.gov](mailto:tickbornedisease@hhs.gov) before May 4, 2019.

The public will have an opportunity to present their views to the Working Group during the meeting's public comment session or by submitting their views in writing. Comments should be pertinent to the meeting discussion. Persons who wish to provide in-person or written public comment should review instructions at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2019-6-4/index.html> and respond by midnight Tuesday, May 28, 2019, ET. In-person comments will be limited to three minutes each to accommodate as many speakers as possible during the 30 minute session. Written public comments will be accessible to the Working Group members and public on the Working Group web page prior to the meeting.

**Background and Authority:** The Tick-Borne Disease Working Group was established on August 10, 2017, in accordance with Section 2062 of the *21st Century Cures Act*, and the Federal Advisory Committee Act, 5 U.S.C. App., as amended, to provide expertise and review federal efforts related to tick-borne diseases to help ensure interagency coordination and minimize overlap, examine research priorities, and identify and address unmet needs. The Working Group is required to submit a report to the HHS Secretary and Congress on their findings and any recommendations for the federal response to tick-borne disease every two years.

Dated: April 26, 2019.

**James Berger,**

*Designated Federal Officer, Tick-Borne Disease Working Group, Senior Advisor for Blood and Tissue Policy, Office of HIV/AIDS and Infectious Disease Policy.*

[FR Doc. 2019-09545 Filed 5-8-19; 8:45 am]

**BILLING CODE 4150-28-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Center for Advancing Translational Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The cooperative agreement and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center for Advancing Translational Sciences Special Emphasis Panel; HEAL Review.

**Date:** June 10, 2019.

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate cooperative agreement applications.

**Place:** Bethesda Marriott Suites, The Patriot Ballroom, 6711 Democracy Boulevard, Bethesda, MD 20817.

**Contact Person:** Christine A. Livingston, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1073, Bethesda, MD 20892, (301) 435-1348, [livingsc@mail.nih.gov](mailto:livingsc@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: May 3, 2019.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-09502 Filed 5-8-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Center for Advancing Translational Sciences; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Collaborative Innovation Awards Review Meeting.

**Date:** June 4, 2019.

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

**Contact Person:** M. Lourdes Ponce, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1073, Bethesda, MD 20892, 301-435-0810, [lourdes.ponce@nih.gov](mailto:lourdes.ponce@nih.gov).

**Name of Committee:** National Center for Advancing Translational Sciences Special Emphasis Panel; Platform Delivery Technologies for Nucleic Acid Therapeutics.

**Date:** June 19, 2019.

**Time:** 8:30 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

**Contact Person:** Jing Chen, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892-4874, [chenjing@mail.nih.gov](mailto:chenjing@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: May 3, 2019.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-09504 Filed 5-8-19; 8:45 am]

**BILLING CODE 4140-01-P**